CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...